The above being said, as I said in a previous post

Quote:

---

The above being said, as I said in a previous post, I don't believe that big pharma (or the world for that matter) has seen an animal like CYDY with all of the POTENTIAL (a dirty word) that Vyrologix has, so it is quite possible that any deal with big pharma could be far more CYDY-centric than previous deals in history. If all goes as we hope it will, CYDY is bringing more to the table than any other drug company ever has.

---

Nader has probably alienated quite a few big pharma companies. When dealing with small non-revenue biotechs they must be used to the companies groveling at their feet to get a seat at the table and a small slice of the pie. An upstart like Cytodyn turning down deals must be making them apoplectic.

Big pharma is going to want all indications. Having the market sliced up and having to compete against other pharmas or Cytodyn itself wouldn't work.

Typically big pharma might offer development costs, decent upfront money and at most a 20% cut of the net. This allows the small biotech the money to develop other drugs in the pipeline. Cytodyn is atypical, we only have one drug. Big upfront money doesn't carry as much weight if the big pharma is developing the drug.

Even with a small upfront I don't see big pharma offering more than 30%. Now take into consideration that Cytodyn might be left with the burden of paying 10% royalties on 100% of the sales then that 30% of net will be very paltry indeed.

So what's the best path forward? Just keep on keeping on what we are doing. Minimize dilution until first approval and revenue. Leverage that revenue to get trials started for a dozen new indications. At that point the world is ours.